These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15226212)

  • 1. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.
    Howard BV; Hsia J; Ouyang P; Van Voorhees L; Lindsay J; Silverman A; Alderman EL; Tripputi M; Waters DD
    Circulation; 2004 Jul; 110(2):201-6. PubMed ID: 15226212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.
    Herrington DM; Reboussin DM; Brosnihan KB; Sharp PC; Shumaker SA; Snyder TE; Furberg CD; Kowalchuk GJ; Stuckey TD; Rogers WJ; Givens DH; Waters D
    N Engl J Med; 2000 Aug; 343(8):522-9. PubMed ID: 10954759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of progression of coronary calcium in postmenopausal women on versus not on estrogen/progestin therapy.
    Becker A; Leber A; von Ziegler F; Becker C; Knez A
    Am J Cardiol; 2007 Feb; 99(3):374-8. PubMed ID: 17261401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
    N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse pressure and coronary atherosclerosis progression in postmenopausal women.
    Nair GV; Waters D; Rogers W; Kowalchuk GJ; Stuckey TD; Herrington DM
    Hypertension; 2005 Jan; 45(1):53-7. PubMed ID: 15545509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study.
    Zhang Y; Howard BV; Cowan LD; Welty TK; Schaefer CF; Wild RA; Yeh J; Lee ET
    J Womens Health (Larchmt); 2004 Mar; 13(2):155-63. PubMed ID: 15072729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.
    Hsia J; Langer RD; Manson JE; Kuller L; Johnson KC; Hendrix SL; Pettinger M; Heckbert SR; Greep N; Crawford S; Eaton CB; Kostis JB; Caralis P; Prentice R;
    Arch Intern Med; 2006 Feb; 166(3):357-65. PubMed ID: 16476878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
    Chlebowski RT; Anderson GL; Gass M; Lane DS; Aragaki AK; Kuller LH; Manson JE; Stefanick ML; Ockene J; Sarto GE; Johnson KC; Wactawski-Wende J; Ravdin PM; Schenken R; Hendrix SL; Rajkovic A; Rohan TE; Yasmeen S; Prentice RL;
    JAMA; 2010 Oct; 304(15):1684-92. PubMed ID: 20959578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.
    Hodis HN; Mack WJ; Azen SP; Lobo RA; Shoupe D; Mahrer PR; Faxon DP; Cashin-Hemphill L; Sanmarco ME; French WJ; Shook TL; Gaarder TD; Mehra AO; Rabbani R; Sevanian A; Shil AB; Torres M; Vogelbach KH; Selzer RH;
    N Engl J Med; 2003 Aug; 349(6):535-45. PubMed ID: 12904518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
    Patel D; Ahmad S; Silverman A; Lindsay J
    Am J Cardiol; 2013 Jun; 111(12):1681-7. PubMed ID: 23499273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose intolerance, insulin resistance and metabolic syndrome in patients with stable angina pectoris. Obesity predicts coronary atherosclerosis and dysglycemia.
    Włodarczyk A; Strojek K
    Pol Arch Med Wewn; 2008 Dec; 118(12):719-26. PubMed ID: 19202950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.
    Hammana I; Malet A; Costa M; Brochiero E; Berthiaume Y; Potvin S; Chiasson JL; Coderre L; Rabasa-Lhoret R
    Diabetes Metab; 2007 Jun; 33(3):213-9. PubMed ID: 17418606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy.
    Kalyan S; Hitchcock CL; Sirrs S; Pudek M; Prior JC
    Pharmacotherapy; 2010 May; 30(5):442-52. PubMed ID: 20411996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of worsening insulin sensitivity in postmenopausal women.
    Goodrow GJ; L'Hommedieu GD; Gannon B; Sites CK
    Am J Obstet Gynecol; 2006 Feb; 194(2):355-61. PubMed ID: 16458629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.